Announcements Trials
Browse Landscape

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1387Neoplasms 1164Colorectal Neoplasms 624Lung Neoplasms 559Prostatic Neoplasms 538Carcinoma, Non-Small-Cell Lung 443Carcinoma, Hepatocellular 296Stomach Neoplasms 272Pancreatic Neoplasms 270Colonic Neoplasms 264Ovarian Neoplasms 230Head and Neck Neoplasms 228Rectal Neoplasms 221Melanoma 215Multiple Myeloma 202Uterine Cervical Neoplasms 198Lymphoma 195Leukemia 193Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Neoplasm Metastasis 178Carcinoma, Renal Cell 177Esophageal Neoplasms 173Brain Neoplasms 173Leukemia, Myeloid, Acute 158Urinary Bladder Neoplasms 138Recurrence 123Polycystic Ovary Syndrome 122Liver Neoplasms 118Hematologic Neoplasms 117Endometrial Neoplasms 107

Interventions

Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Observational × HER2+ Breast Cancer × Clear all
NCT05931042 2023-07-05

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Rawalpindi Medical College

Completed
1,209 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡